• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Dr. Reddy's Laboratories Ltd (Amendment)

    5/2/22 2:44:27 PM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RDY alert in real time by email
    SC 13D/A 1 drr0386_sc13da.htm AMENDMENT NO. 4 TO SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C.  20549

     

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

    Dr. Reddy’s Laboratories Limited

    (Name of Issuer)

     

    American depositary shares, each representing one equity share

    (Title of Class of Securities)

     

    256135203

    (CUSIP Number)

     

    Jonathan Gray, Esq.

    Windels Marx Lane & Mittendorf, LLP

    120 Albany Street Plaza, 6th Floor

    New Brunswick, NJ 08901

    (732) 846-7600

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    April 22, 2022

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

       

     

     

    CUSIP No:   256135203  Page 2 of 10 Pages

     

    1.

    Names of Reporting Persons.      Dr. Reddy’s Holdings Limited (formerly Dr. Reddy’s Holdings Private Limited)

     

    S.S. or I.R.S. Identification Nos. of Above Persons (Entities Only): N/A

     

    2.

    Check the Appropriate Box if a Member of a Group

     

    (a) ¨

    (b) x

    3.

    SEC Use Only

     

    4.

    Source of Funds (See Instructions)

     

    PF

    5.

    Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

     

    ¨

     

    6.

    Citizenship or Place of Organization

     

    Republic of India

     

    Number of

    Shares

    Beneficially

    Owned by Each

    Reporting

    Person With

     

    7. Sole Voting Power 0*
    8. Shared Voting Power 0*
    9. Sole Dispositive Power 0*
    10. Shared Dispositive Power 0*

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0*

     

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ¨ Beneficial ownership disclaimed pursuant to Rule 13d-4

    13.

    Percent of Class Represented by Amount in Row (11)

     

    0%*

     

    14.

    Type of Reporting Person:

     

    CO

     

        

    *Pursuant to a Scheme of Amalgamation and Arrangement under the Indian Companies Act, 2013, Dr. Reddy’s Holdings Limited was merged out of existence, with Dr. Reddy’s Laboratories Limited as the surviving entity in the merger, and equity shares of Dr. Reddy’s Laboratories Limited were issued to the shareholders of Dr. Reddy’s Holdings Limited, who accordingly became direct holders of equity shares in Dr. Reddy’s Laboratories Limited (equal to the number of shares that they held indirectly through Dr. Reddy’s Holdings Limited immediately prior to the merger) on April 22, 2022. As a result, Dr. Reddy’s Holdings Limited is no longer an owner of the 41,325,300 equity shares of Dr. Reddy’s Laboratories Limited.

     

       

     

     

    CUSIP No:   256135203  Page 3 of 10 Pages

     

    1.

    Names of Reporting Persons. APS Trust

     

    S.S. or I.R.S. Identification Nos. of Above Persons (Entities Only): N/A

     

    2.

    Check the Appropriate Box if a Member of a Group

     

    (a) ¨

    (b) x

    3.

    SEC Use Only

     

    4.

    Source of Funds (See Instructions)

     

    PF

    5.

    Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

     

    ¨

     

    6.

    Citizenship or Place of Organization

     

    Republic of India

     

    Number of

    Shares

    Beneficially

    Owned by Each

    Reporting

    Person With

     

    7. Sole Voting Power 34,345,308
    8. Shared Voting Power

    44,461,128*

    9. Sole Dispositive Power 34,345,308
    10. Shared Dispositive Power

    44,461,128*

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    44,461,128

     

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    x Beneficial ownership disclaimed pursuant to Rule 13d-4

    13.

    Percent of Class Represented by Amount in Row (11)

     

    26.72%

     

    14.

    Type of Reporting Person:

     

    OOF

     

    *The APS Trust owns 34,345,308 equity shares of Dr. Reddy’s Laboratories Limited. In addition, the Deed of Family Settlement of the APS Trust provides for the parties thereto to exercise all rights, including voting rights, with respect to their personally held Equity Shares in accordance with the directions of the board of trustees of the APS Trust (see item 6. below) and, as a result, the APS Trust may be deemed to beneficially own all of the Equity Shares directly held by each of Mr. G.V. Prasad, the G.V. Prasad HUF, Mrs. K. Samrajyam (mother of Mr. K. Satish Reddy), Mr. K. Satish Reddy, the K. Satish Reddy HUF, Mrs. G. Anuradha (wife of Mr. G.V. Prasad), K. Deepti Reddy (wife of Mr. K Satish Reddy), and Sharatchandra Reddy Gunupati, G.V. Sanjana Reddy and G. Mallika Reddy (children of Mr. G.V. Prasad). The APS Trust disclaims such beneficial ownership pursuant to Rule 13d-4. 

     

       

     

     

    CUSIP No:   256135203  Page 4 of 10 Pages

     

    1.

    Names of Reporting Persons.        Mr. G.V. Prasad

     

    S.S. or I.R.S. Identification Nos. of Above Persons (Entities Only): N/A

     

    2.

    Check the Appropriate Box if a Member of a Group

     

    (a) ¨

    (b) x

    3.

    SEC Use Only

     

    4.

    Source of Funds (See Instructions)

     

    PF and AF

    5.

    Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

     

    ¨ 

     

    6.

    Citizenship or Place of Organization

     

    Republic of India

     

    Number of

    Shares

    Beneficially

    Owned by Each

    Reporting

    Person With

     

    7. Sole Voting Power 0
    8. Shared Voting Power 44,461,128*
    9. Sole Dispositive Power 0
    10. Shared Dispositive Power

    44,461,128*

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    44,461,128

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    x Beneficial ownership disclaimed pursuant to Rule 13d-4

    13.

    Percent of Class Represented by Amount in Row (11)

     

    26.72%*

     

    14.

    Type of Reporting Person:

     

    IN

      

    *The APS Trust owns 34,345,308 equity shares of Dr. Reddy’s Laboratories Limited, and Mr. G.V. Prasad is one of the two trustees of the APS Trust. Accordingly, Mr. G.V. Prasad may be deemed to beneficially own all of the equity shares directly held by the APS Trust. Mr. G.V. Prasad disclaims such beneficial ownership pursuant to Rule 13d-4.

     

    In addition, the Deed of Family Settlement of the APS Trust provides for the parties thereto to exercise all rights, including voting rights, with respect to their personally held Equity Shares in accordance with the directions of the board of trustees of the APS Trust (see item 6. below) and, as a result, Mr. G.V. Prasad may be deemed to beneficially own all of the Equity Shares directly held by each of the G.V. Prasad HUF, Mrs. K. Samrajyam (mother of Mr. K. Satish Reddy), Mr. K. Satish Reddy, the K. Satish Reddy HUF, Mrs. G. Anuradha (wife of Mr. G.V. Prasad), K. Deepti Reddy (wife of Mr. K Satish Reddy), and Sharatchandra Reddy Gunupati, G.V. Sanjana Reddy and G. Mallika Reddy (children of Mr. G.V. Prasad). Mr. G.V. Prasad disclaims such beneficial ownership pursuant to Rule 13d-4.

     

       

     

     

    CUSIP No:   256135203  Page 5 of 10 Pages

     

    1.

    Names of Reporting Persons.        Mr. K. Satish Reddy

     

    S.S. or I.R.S. Identification Nos. of Above Persons (Entities Only): N/A

     

    2.

    Check the Appropriate Box if a Member of a Group

     

    (a) ¨

    (b) x

    3.

    SEC Use Only

     

    4.

    Source of Funds (See Instructions)

     

    PF and AF

    5.

    Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

     

    ¨

     

    6.

    Citizenship or Place of Organization

     

    Republic of India

     

    Number of

    Shares

    Beneficially

    Owned by Each

    Reporting

    Person With

     

    7. Sole Voting Power 901,002
    8. Shared Voting Power 44,461,128*  
    9. Sole Dispositive Power 901,002
    10. Shared Dispositive Power 44,461,128*

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person 

    44,461,128*

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    x Beneficial ownership disclaimed pursuant to Rule 13d-4

    13.

    Percent of Class Represented by Amount in Row (11) 

    26.72%*

     

    14.

    Type of Reporting Person:

     

    IN

     

      

    * The APS Trust owns 34,345,308 equity shares of Dr. Reddy’s Laboratories Limited, and Mr. K. Satish Reddy is one of the two trustees of the APS Trust. Accordingly, Mr. K. Satish Reddy may be deemed to beneficially own all of the equity shares directly held by the APS Trust. Mr. K. Satish Reddy disclaims such beneficial ownership pursuant to Rule 13d-4.

     

    In addition, the Deed of Family Settlement of the APS Trust provides for the parties thereto to exercise all rights, including voting rights, with respect to their personally held Equity Shares in accordance with the directions of the board of trustees of the APS Trust (see item 6. below) and, as a result, Mr. K. Satish Reddy may be deemed to beneficially own all of the Equity Shares directly held by each of the K. Satish Reddy HUF, Mrs. K. Samrajyam (mother of Mr. K. Satish Reddy), Mr. G.V. Prasad, the G.V. Prasad HUF, Mrs. G. Anuradha (wife of Mr. G.V. Prasad), K. Deepti Reddy (wife of Mr. K Satish Reddy), and Sharatchandra Reddy Gunupati, G.V. Sanjana Reddy and G. Mallika Reddy (children of Mr. G.V. Prasad). Mr. K. Satish Reddy disclaims such beneficial ownership pursuant to Rule 13d-4.

     

       

     

     

       Page 6 of 10 Pages

     

    SCHEDULE 13D

     

    Item 1.Security and Issuer

     

    This Amendment No. 4 to Schedule 13D (this “Amendment No. 4”) further amends and supplements the Schedule 13D of Dr. Reddy’s Holdings Limited (formerly Dr. Reddy’s Holdings Private Limited) and Dr. K. Anji Reddy on February 15, 2002 (the “Original Schedule 13D”) with respect to the american depositary shares (“ADSs”), each representing one equity share (the “Equity Shares”), of Dr. Reddy’s Laboratories Limited (the “Issuer” or the “Company”), as amended by that certain Amendment No. 1 filed on February 3, 2016 by Dr. Reddy’s Holdings Limited, the APS Trust, Mr. G.V. Prasad and Mr. K. Satish Reddy (“Amendment No. 1”), and as further amended by that certain Amendment No. 2 filed on January 16, 2017 by Dr. Reddy’s Holdings Limited, the APS Trust, Mr. G.V. Prasad and Mr. K. Satish Reddy (“Amendment No. 2”), and as further amended by that certain Amendment No. 3 filed on October 18, 2017 by Dr. Reddy’s Holdings Limited, the APS Trust, Mr. G.V. Prasad and Mr. K. Satish Reddy (“Amendment No. 3” and, together with the Original Schedule 13D, Amendment No. 1, Amendment No. 2 and Amendment No. 3, collectively, the “Amended Schedule 13D”). The Company’s principal executive offices are located at 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500 034, India. 

     

    This Amendment No. 4 is being filed to report the following changes:

     

    (i)Pursuant to a Scheme of Amalgamation and Arrangement under the Indian Companies Act, 2013 (the “Scheme of Amalgamation”), Dr. Reddy’s Holdings Limited (“DRHL”) was merged out of existence (the “Merger”), with the Company as the surviving entity in the Merger, and equity shares of the Company were issued to the shareholders of DRHL, who accordingly became direct holders of equity shares in the Company (equal to the number of shares that they held indirectly through DRHL immediately prior to the Merger) on April 22, 2022.

     

    (ii)the following changes with respect to Mr. G.V. Prasad:

     

    (A)Mr. G.V. Prasad’s market purchases of 59,700 Equity Shares during the month of May 2018.

     

    (B)Mr. G.V. Prasad’s pledge of 318,100 Equity Shares to Julius Baer Capital (India) Private Limited as security for a loan was released in August 2018.

     

    (C)Mr. G.V. Prasad’s transfer of Equity Shares to DRHL as follows: a transfer of 80,000 Equity Shares on or around August 13, 2018; a transfer of 1,900 Equity Shares on or around September 10, 2018; and a transfer of 39,000 Equity Shares on or around September 26, 2018.

     

    (D)       Mr. G.V. Prasad’s transfer of 1,117,940 Equity Shares to the G.V. Prasad HUF on or around March 26, 2021.

     

    (iii)Mr. K. Satish Reddy's transfer of Equity Shares to DRHL as follows: a transfer of 80,000 Equity Shares on or around August 13, 2018; a transfer of 1,900 Equity Shares on or around September 10, 2018; and a transfer of 39,000 Equity Shares on or around September 26, 2018.

     

    Item 2.Identity and Background

     

    Item 2 of the Amended Schedule 13D is hereby amended and supplemented as follows:

     

    (a)-(c) The persons filing this Amendment No. 4 are (i) the Company, on behalf of and as successor by merger to Dr. Reddy’s Holdings Limited (formerly Dr. Reddy’s Holdings Private Limited), an Indian corporation; (ii) the APS Trust, a trust formed under the laws of India; (iii) Mr. G.V. Prasad, the Co-Chairman and Managing Director of the Company; and (iv) Mr. K. Satish Reddy, Chairman of the Company. The address of each of them is 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500 034, India, telephone +91-40-49002900.

     

    The APS Trust directly holds 34,345,308 Equity Shares of the Company as of April 22, 2022, representing approximately 20.64% of the outstanding Equity Shares of the Company as of such date. Mr. G.V. Prasad, Mr. K. Satish Reddy, Mrs. G. Anuradha, Mrs. Deepti Reddy and their bloodline descendants and Hindu Undivided Families (“HUF”) are the beneficiaries of the APS Trust.

     

    Mr. G.V. Prasad and Mr. K. Satish Reddy are the sole trustees of the APS Trust and thus may be deemed to beneficially own all of the Equity Shares directly held by the APS Trust. Accordingly, each of Mr. G.V. Prasad and Mr. K. Satish Reddy may be deemed to beneficially own all of the Equity Shares directly held by the APS Trust. Each of Mr. G.V. Prasad and Mr. K. Satish Reddy disclaims such beneficial ownership pursuant to Rule 13d-4.

     

       

     

     

       Page 7 of 10 Pages

     

    In addition, the Deed of Family Settlement of the APS Trust provides for the parties thereto to exercise all rights, including voting rights, with respect to their personally held Equity Shares in accordance with the directions of the board of trustees of the APS Trust (see item 6. below). As a result, in addition to the 901,002 Equity Shares directly held by him, Mr. K. Satish Reddy may be deemed to beneficially own all of the 5,523,677 Equity Shares directly held by the K. Satish Reddy HUF, the 2,543,418 Equity Shares directly held by the G.V. Prasad HUF, the 1,120,499 Equity Shares directly held by Mrs. K. Samrajyam (mother of Mr. K. Satish Reddy), and the 9,205 Equity Shares directly held by Mrs. G. Anuradha (wife of Mr. G.V. Prasad). Similarly, Mr. G.V. Prasad may be deemed to beneficially own all of the 901,002 Equity Shares directly held by Mr. K. Satish Reddy, the 5,523,677 Equity Shares directly held by the K. Satish Reddy HUF, the 2,543,418 Equity Shares directly held by the G.V. Prasad HUF, the 1,120,499 Equity Shares directly held by Mrs. K. Samrajyam (mother of Mr. K. Satish Reddy), and the 9,205 Equity Shares directly held by Mrs. G. Anuradha (wife of Mr. G.V. Prasad). Each of Mr. G.V. Prasad and Mr. K. Satish Reddy disclaims all such beneficial ownership pursuant to Rule 13d-4.

     

    (d)          The persons filing this Amendment No. 4 have not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)          The persons filing this Amendment No. 4 have not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)           Each of Mr. G.V. Prasad and Mr. K. Satish Reddy is a citizen of the Republic of India.

     

    Item 3. Source and Amount of Funds or Other Consideration

     

    Item 3 of the Amended Schedule 13D is hereby amended and supplemented as follows:

     

    The APS Trust. The APS Trust directly owns 34,345,308 Equity Shares, and the source of funds for such Equity Shares are as follows:

     

    ·Prior to the Merger, DRHL held 41,325,300 of the Equity Shares (after giving effect to the Company’s August 30, 2006 stock split, effected as a one-for-one Equity Share divided) since prior to the effective date of the Company’s registration statement on Form F-1. The source of funds for the acquisition of the remaining Equity Shares held by Dr. Reddy’s Holdings Limited was funds generated from dividends on Equity Shares of the Company paid to Dr. Reddy’s Holdings Limited.

     

    ·Prior to the Merger, the APS Trust owned approximately 83.11% of the equity of DRHL. In connection with the Merger (as described in Item 1 above), the Company issued 34,345,308 Equity Shares to the APS Trust on April 22, 2022 as consideration for the Merger. Accordingly, the foregoing is the source of funds for the 34,345,308 Equity Shares directly owned by the APS Trust.

     

    In addition, the APS Trust may be deemed to beneficially own all of the Equity Shares directly held by Mr. G.V. Prasad and Mr. K. Satish Reddy (see their respective source of funds discussions below).

     

    Mr. G.V. Prasad. Mr. G.V. Prasad does not directly own any Equity Shares, but he owns 2,543,418 Equity Shares indirectly through the G.V. Prasad HUF. The G.V. Prasad HUF directly owns 2,543,418 Equity Shares, and the source of funds for such Equity Shares are as follows:

     

    ·Prior to the Merger, the G.V. Prasad HUF directly owned 1,117,940 Equity Shares, all of which were transferred to it by G.V. Prasad on or around March 26, 2021 for estate planning purposes. All such 1,117,940 Equity Shares were acquired by Mr. G.V. Prasad through his personal funds prior to such transfer to such HUF. An aggregate of 250,500 of such Equity Shares were acquired by him pursuant to open market transactions on stock exchanges. The remainder of such Equity Shares had been held by him since prior to the effective date of the Company’s registration statement on Form F-1.

     

    ·In addition, the G.V. Prasad HUF was previously a shareholder of DRHL and, in connection with the Merger, the Company issued an additional 1,425,478 Equity Shares to the G.V. Prasad HUF on April 22, 2022 as consideration for the Merger. Accordingly, the foregoing is the source of funds for 1,425,478 of the Equity Shares directly owned by the G.V. Prasad HUF.

     

    In addition, Mr. G.V. Prasad may be deemed to beneficially own all of the Equity Shares directly held by the APS Trust (see the APS Trust source of funds discussion above).

     

       

     

     

       Page 8 of 10 Pages

     

    Mr. K. Satish Reddy. Mr. K. Satish Reddy directly owns 901,002 Equity Shares, and the source of funds for such Equity Shares are as follows:

     

    ·Prior to the Merger, Mr. K. Satish Reddy directly owned 898,432 Equity Shares, all of which were acquired through his personal funds and/or funds previously borrowed from Citicorp Finance (India) Limited, as more particularly described in Item 6 of Amendment No. 2. As described in Item 1 of Amendment No. 2, 316,500 of such Equity Shares were acquired by him pursuant to open market transactions on stock exchanges. The remainder of such Equity Shares have been held by him since prior to the effective date of the Company’s registration statement on Form F-1.

     

    ·In addition, Mr. K. Satish Reddy was previously a shareholder of DRHL and, in connection with the Merger, the Company issued an additional 2,570 Equity Shares to Mr. K. Satish Reddy on April 22, 2022 as consideration for the Merger. Accordingly, the foregoing is the source of funds for 2,570 of the Equity Shares directly owned by Mr. K. Satish Reddy.

     

    In addition, Mr. K. Satish Reddy owns 5,523,677 Equity Shares indirectly through the K. Satish Reddy HUF. The K. Satish Reddy HUF directly owns 5,523,677 Equity Shares, and the source of funds for such Equity Shares are as follows:

     

    ·The K. Satish Reddy HUF was previously a shareholder of DRHL and, in connection with the Merger, the Company issued an 5,523,677 Equity Shares to the K. Satish Reddy HUF on April 22, 2022 as consideration for the Merger. Accordingly, the foregoing is the source of funds for all 5,523,677 of the Equity Shares directly owned by the K. Satish Reddy HUF.

     

    In addition, Mr. K. Satish Reddy may be deemed to beneficially own all of the Equity Shares directly held by the APS Trust (see the APS Trust source of funds discussion above).

     

    Item 4.Purpose of the Transaction

     

    Item 4 of the Amended Schedule 13D is hereby amended and supplemented as follows:

     

    Pursuant to the Scheme of Amalgamation, DRHL was merged out of existence, with the Company as the surviving entity in the Merger, and equity shares of the Company were issued to the shareholders of DRHL, who accordingly became direct holders of equity shares in the Company (equal to the number of shares that they held indirectly through DRHL immediately prior to the Merger) on April 22, 2022. The Merger simplified the Company’s shareholding structure and reduced its shareholding tiers.

     

    Item 5.Interest in Securities of the Issuer

     

    Item 5 of the Amended Schedule 13D is hereby amended and supplemented as follows:

     

    (a)          The APS Trust directly owns 34,345,308 Equity Shares as of April 22, 2022, immediately after giving effect to the Merger. Mr. G.V. Prasad and Mr. K. Satish Reddy are the sole trustees of the APS Trust. Accordingly, each of Mr. G.V. Prasad and Mr. K. Satish Reddy may be deemed to beneficially own all of the Equity Shares directly held by the APS Trust. Each of Mr. G.V. Prasad and Mr. K. Satish Reddy disclaims such beneficial ownership pursuant to Rule 13d-4.

     

    In addition, the Deed of Family Settlement of the APS Trust provides for the parties thereto to exercise all rights, including voting rights, with respect to their personally held Equity Shares in accordance with the directions of the board of trustees of the APS Trust (see item 6. below). As a result, in addition to the 901,002 Equity Shares directly held by him, Mr. K. Satish Reddy may be deemed to beneficially own all of the 5,523,677 Equity Shares directly held by the K. Satish Reddy HUF, the 2,543,418 Equity Shares directly held by the G.V. Prasad HUF, the 1,120,499 Equity Shares directly held by Mrs. K. Samrajyam (mother of Mr. K. Satish Reddy), and the 9,205 Equity Shares directly held by Mrs. G. Anuradha (wife of Mr. G.V. Prasad). Similarly, Mr. G.V. Prasad may be deemed to beneficially own all of the 901,002 Equity Shares directly held by Mr. K. Satish Reddy, the 5,523,677 Equity Shares directly held by the K. Satish Reddy HUF, the 2,543,418 Equity Shares directly held by the G.V. Prasad HUF, the 1,120,499 Equity Shares directly held by Mrs. K. Samrajyam (mother of Mr. K. Satish Reddy), and the 9,205 Equity Shares directly held by Mrs. G. Anuradha (wife of Mr. G.V. Prasad). Each of Mr. G.V. Prasad and Mr. K. Satish Reddy disclaims all such beneficial ownership pursuant to Rule 13d-4.

     

    (b)          Mr. K. Satish Reddy has the sole power to vote or direct the vote and to dispose or to direct the disposition of the 901,002 Equity Shares directly held by him.

     

       

     

     

       Page 9 of 10 Pages

     

    Each of Mr. G.V. Prasad and Mr. K. Satish Reddy may be deemed to share the power to vote or direct the vote and to dispose or to direct the disposition of all of the 34,345,308 Equity Shares directly held by the APS Trust. Each of Mr. G.V. Prasad and Mr. K. Satish Reddy disclaims any beneficial ownership of such Equity Shares pursuant to Rule 13d-4.

     

    Mr. K. Satish Reddy may also be deemed to share the power to vote or direct the vote and to dispose or to direct the disposition of the 5,523,677 Equity Shares directly held by the K. Satish Reddy HUF, the 2,543,418 Equity Shares directly held by the G.V. Prasad HUF, the 1,120,499 Equity Shares directly held by Mrs. K. Samrajyam (mother of Mr. K. Satish Reddy), and the 9,205 Equity Shares directly held by Mrs. G. Anuradha (wife of Mr. G.V. Prasad).

     

    In addition, Mr. G.V. Prasad may also be deemed to share the power to vote or direct the vote and to dispose or to direct the disposition of the 901,002 Equity Shares directly held by Mr. K. Satish Reddy, the 5,523,677 Equity Shares directly held by the K. Satish Reddy HUF, the 2,543,418 Equity Shares directly held by the G.V. Prasad HUF, the 1,120,499 Equity Shares directly held by Mrs. K. Samrajyam (mother of Mr. K. Satish Reddy), and the 9,205 Equity Shares directly held by Mrs. G. Anuradha (wife of Mr. G.V. Prasad). Each of Mr. G.V. Prasad and Mr. K. Satish Reddy disclaims all such beneficial ownership pursuant to Rule 13d-4.

     

    (c)          None of the reporting persons have purchased Equity Shares of the Company within the past 60 days.

     

    Item 6.Contracts, Agreements, Understandings or Relationships with Respect to Securities of the Issuer

     

    Item 6 of the Amended Schedule 13D is hereby amended and supplemented as follows:

     

    The APS Trust is governed by a Deed of Family Settlement dated May 13, 2011 (the “Deed of Family Settlement”) by and among Dr. K. Anji Reddy, Mr. K. Satish Reddy, Mr. G.V. Prasad and certain of their respective family members and Hindu Undivided Families (“HUF”). Pursuant to the Deed of Family Settlement, the parties thereto have agreed that, with respect to the shares held by them from time to time in the Company or Dr. Reddy’s Holdings Limited, they: (a) shall exercise all rights, including voting rights, with respect to such shares in accordance with the directions of the board of trustees of the APS Trust; (b) shall not transfer any such shares to any person other than (i) the APS Trust, (ii) an entity controlled by the APS Trust, or (iii) Dr. K. Anji Reddy, Mr. K. Satish Reddy, Mr. G.V. Prasad or their respective family members and HUFs; and (c) shall be subject to certain call rights with respect to beneficial interests in the APS Trust in the event of a deadlock of the board of trustees with respect to certain matters. The Deed of Family Settlement was attached as Exhibit 99.2 to Amendment No. 1 to the Original Schedule 13D, which was filed on February 3, 2016.

     

    Mr. G.V. Prasad’s prior pledge of 318,100 Equity Shares to Julius Baer Capital (India) Private Limited as security for a loan (pursuant to the Loan Agreements and Pledge Agreements attached as exhibits to Amendment No. 3) was released in August 2018

     

    Item 7.Materials to be filed as Exhibits

     

    99.1.Joint Filing Agreement of the Reporting Persons.

     

       

     

       Page 10 of 10 Pages

     

    AMENDMENT NO. 4 TO SCHEDULE 13D

     

    SIGNATURE

     

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

      Dr. Reddy’s Holdings Limited    
             
      By:   Dr. Reddy’s Laboratories Limited,    
        its successor by merger    
      By: /s/ K. Satish Reddy    
        Name: K. Satish Reddy    
        Title:   Chairman    

     

      APS Trust    
             
      By: /s/ G.V. Prasad  
        Name: G.V. Prasad    
        Title:   Trustee    
             
      By: /s/ K. Satish Reddy  
        Name: K. Satish Reddy    
        Title:   Trustee    

     

      G.V. Prasad      
               
      By: /s/ G.V. Prasad  
               
      K. Satish Reddy      
               
      By: /s/ K. Satish Reddy  

     

    May 2, 2022

     

    Attention: Intentional misstatements or omissions of act constitute federal violations (see 18 U.S.C. 1001).

     

       

     

    Get the next $RDY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RDY

    DatePrice TargetRatingAnalyst
    12/19/2024Buy → Neutral
    Nomura
    1/11/2024Buy → Underperform
    Jefferies
    8/29/2023Buy → Hold
    HSBC Securities
    5/18/2023Outperform → Mkt Perform
    Bernstein
    3/17/2023Neutral → Buy
    BofA Securities
    1/30/2023Underweight
    JP Morgan
    11/14/2022Neutral → Underperform
    Credit Suisse
    1/3/2022Neutral
    BofA Securities
    More analyst ratings

    $RDY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Dr. Reddy's Laboratories Ltd

      SC 13D/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)

      7/1/24 6:44:13 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Dr. Reddy's Laboratories Ltd (Amendment)

      SC 13D/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)

      5/2/22 2:44:27 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)

      2/2/21 7:05:59 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dr. Reddy's Q4 & Full Year FY25 Financial Results

      Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY25 FY25   Revenues ₹ 85,060 Mn ₹ 325,535 Mn [Up: 20% YoY^; 2% QoQ] [Up: 17% YoY^]     Gross Margin 55.6% 58.5% [Q4FY24: 58.6%; Q3FY25: 58.7%] [FY24: 58.6%]     SG&A Expenses ₹ 24,055 Mn ₹ 93,870 Mn [Up: 17% YoY; Flat QoQ] [Up: 22% YoY]     R&D Expens

      5/9/25 2:53:00 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

      GUANGZHOU, China and HYDERABAD, India, March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as ", Dr. Reddy', s", ), announce today they have reached commercialization and license agreements for BAT2206, a proposed Stelara® biosimilar, and BAT2506, a proposed Simponi® biosimilar.

      3/27/25 11:47:00 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

      Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") and Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted a 351(k) Biologic License Application (BLA) submission for AVT03, developed by Alvotech, a proposed biosimilar of Prolia® (denosumab) and Xgeva® (denosumab). "The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients t

      3/18/25 8:35:00 AM ET
      $ALVO
      $RDY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $RDY
    SEC Filings

    See more
    • SEC Form 6-K filed by Dr. Reddy's Laboratories Ltd

      6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)

      5/15/25 9:15:27 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Dr. Reddy's Laboratories Ltd

      6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)

      5/14/25 6:18:45 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Dr. Reddy's Laboratories Ltd

      6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)

      5/12/25 6:27:00 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDY
    Leadership Updates

    Live Leadership Updates

    See more
    • Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

      SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as ", Dr. Reddy', s", ) for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection. Dr. Reddy's will gain exclusive rights to commercialize both subcutaneous and intravenous formulation of HLX15 in a total of 43 countries and regions, comprising 42 European countries and

      2/6/25 6:35:00 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America

      Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as ", Dr. Reddy', s", )), today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America, and member of the Management Council. As part of the Dr. Reddy's senior leadership team, he will be responsible for the company's North America business and will be based out of the Princeton, New Jersey, U.S. office. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528120424/en/Milan Kalawadia (Photo: Business Wire) "I am excited to start this next chapter in my journey at Dr

      5/28/24 9:53:00 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDY
    Financials

    Live finance-specific insights

    See more
    • Dr. Reddy's Q4 & Full Year FY25 Financial Results

      Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY25 FY25   Revenues ₹ 85,060 Mn ₹ 325,535 Mn [Up: 20% YoY^; 2% QoQ] [Up: 17% YoY^]     Gross Margin 55.6% 58.5% [Q4FY24: 58.6%; Q3FY25: 58.7%] [FY24: 58.6%]     SG&A Expenses ₹ 24,055 Mn ₹ 93,870 Mn [Up: 17% YoY; Flat QoQ] [Up: 22% YoY]     R&D Expens

      5/9/25 2:53:00 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's Q3 & 9MFY25 Financial Results

      Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and nine months ended December 31, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q3FY25 9MFY25   Revenues ₹ 83,586 Mn ₹ 240,475 Mn [Up: 16% YoY^; 4% QoQ] [Up: 15% YoY^]   Gross Margin 58.7% 59.5% [Q3FY24: 58.5%; Q2FY25: 59.6%] [9MFY24: 58.6%]   SG&A Expenses ₹ 24,117 Mn ₹ 69,815 Mn [Up: 19% YoY; 5% QoQ] [Up: 23% YoY]   R&D Expenses ₹ 6,658 Mn ₹ 20,122 Mn [8.0% o

      1/23/25 12:35:00 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's Q2 & H1FY25 Financial Results

      Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the quarter and half year ended September 30, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q2FY25 H1FY25   Revenues ₹ 80,162 Mn [Up: 17% YoY; 4% QoQ] ₹ 156,889 Mn [Up: 15% YoY]   Gross Margin 59.6% [Q2FY24: 58.7%; Q1FY25: 60.4%] 60.0% [H1FY24: 58.7%]   SG&A Expenses ₹ 23,007 Mn [Up: 22% YoY; 1% QoQ] ₹ 45,698 Mn [Up: 25% YoY]   R&D Expenses ₹ 7,271 Mn [9.1%

      11/5/24 9:59:00 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dr. Reddy's downgraded by Nomura

      Nomura downgraded Dr. Reddy's from Buy to Neutral

      12/19/24 8:23:54 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's downgraded by Jefferies

      Jefferies downgraded Dr. Reddy's from Buy to Underperform

      1/11/24 8:20:29 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's downgraded by HSBC Securities

      HSBC Securities downgraded Dr. Reddy's from Buy to Hold

      8/29/23 7:17:57 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care